ALKERMES | ALKS - Operating Expenses


ALKERMES reported $1.73B in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
AbbVie USD 10.81B 13.45B Dec/2025
Acadia Pharmaceuticals USD 242.88M 10.68M Sep/2025
ALKERMES USD 1.73B 1.44B Sep/2025
Amgen USD 5.9B 773M Dec/2025
Biogen USD 1.88B 81.4M Sep/2025
BioMarin Pharmaceutical USD 807.82M 259.3M Sep/2025
Bristol-Myers Squibb USD 8.3B 10.25B Dec/2025
Coherus Biosciences USD 53.03M 43.41M Mar/2025
Eli Lilly USD 10.31B 1.09B Dec/2025
Gilead Sciences USD 4.96B 707M Dec/2025
Heron Therapeutics USD 38.47M 4M Sep/2024
Ionis Pharmaceuticals USD 316.9M 4.69M Sep/2025
J&J USD 18.97B 2.38B Dec/2025
Malin Corporation EUR 1.1M 400K Dec/2024
Merck USD 10.16B 558M Dec/2025
Minerva Neurosciences USD 4.52M 155.46K Dec/2024
Nektar Therapeutics USD 85.09M 109.3M Sep/2025
Neurocrine Biosciences USD 577.6M 22M Dec/2025
Otsuka Holdings JPY 582.9B 113.74B Dec/2025
Ovoca Bio EUR 5.65M 3.45M Jun/2022
Pfizer USD 12.91B 79.89B Dec/2025
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Vertex Pharmaceuticals USD 1.93B 89.1M Dec/2025